EMEA-001638-PIP02-21 - paediatric investigation plan | European Medicines Agency (EMA)Skip to main content
EMEA-001638-PIP02-21 - paediatric investigation plan
atezolizumab
PIPHuman
Key facts
Invented name
Tecentriq
Active Substance
atezolizumab
Therapeutic area
Oncology
Decision number
P/0384/2021
PIP number
EMEA-001638-PIP02-21
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, hematopoietic and lymphoid tissue neoplasms and melanoma)